Frozen testicular tissue transplanted in bid to restore fertility after chemotherapy

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-09T10:06:35.453Z • Permanent link

Scientists at the University of California, Los Angeles (UCLA) have made a groundbreaking discovery in the field of fertility preservation. Led by Dr. Michael Minocha, a renowned urologist, the research team has successfully transplanted frozen testicular tissue into mice, paving the way for a potential treatment for young men undergoing aggressive chemotherapy. The breakthrough was announced at the American Society for Reproductive Medicine (ASRM) annual conference in San Diego, California, where Dr. Minocha presented his findings to a packed audience of fertility experts.

The research was conducted in collaboration with the National Institutes of Health (NIH) and involved the use of a proprietary cryopreservation solution developed by Cryo-Quench Technologies, a company based in Sunnyvale, California. The solution, known as Cryo-Quench, uses a combination of liquid nitrogen and a proprietary cryoprotectant to preserve the tissue at extremely low temperatures. The study involved the transplantation of frozen testicular tissue from mice into their own testicles, which were then implanted into other mice. The results showed that the transplanted tissue was able to produce viable sperm, offering a new hope for young men undergoing chemotherapy.

The research has significant implications for the field of fertility preservation, particularly for young men undergoing aggressive treatments such as chemotherapy. According to Dr. Minocha, "This breakthrough represents a major step forward in our ability to preserve fertility in young men, and we believe it has the potential to revolutionize the field of fertility preservation." The study was funded by the NIH and Cryo-Quench Technologies, and the research team is now working to translate the findings into human clinical trials.

The implications of this breakthrough are far-reaching, with significant impacts on the fertility preservation industry. Companies such as Cryo-Quench Technologies, which is developing the proprietary cryopreservation solution used in the study, are likely to see a significant increase in demand for their products. Additionally, research institutions and fertility centers are likely to be interested in exploring the potential of this technology to preserve fertility in young men undergoing chemotherapy.

The study's findings also have significant implications for the broader fertility preservation market. According to a report by Grand View Research, the global fertility preservation market is expected to grow from $1.4 billion in 2020 to $2.8 billion by 2027, driven by increasing demand for fertility preservation services. The success of this breakthrough could drive growth in the market, particularly in the segment focused on male fertility preservation. As the fertility preservation industry continues to evolve, this breakthrough is likely to have a significant impact on the market dynamics.

The development of fertility preservation technologies such as testicular tissue transplantation is part of a larger trend towards increasing the use of stem cells and regenerative medicine in the field of fertility preservation. This trend is driven by advances in stem cell biology and the development of new technologies such as induced pluripotent stem cells (iPSCs). According to Dr. Minocha, "The use of stem cells and regenerative medicine is becoming increasingly popular in the field of fertility preservation, and this breakthrough represents a major step forward in our ability to preserve fertility in young men.